Breast cancer patients who will be recruited for the study with 188Re labeled anti-HER2 sdAb will have positive HER2; progression or relapse after standard treatment, including surgery, chemotherapy, radiotherapy, and targeted therapy; and will receive the radiopharmaceutical in a single dose of injection. This evidence concerns the gene ERBB2 and breast cancer.